Think of it as the confection that holds together a fruitcake. That is how Michael Scholl, CEO of Leukocare, described his company’s surface functionalisation and binding technology to BIOMEDevice Europe attendees. It was one of several papers presented under the thematic umbrella of Enabling Technologies for Manufacturing Combination Products at the event held last week at the Grande Halle de la Villette in Paris.
Leukocare has developed a technique for binding and stabilising functional molecules on the surfaces of medical devices. The company’s key technology is postcoating stabilisation, which preserves molecules for long-term stability and maintains biomolecular functionality. It allows drying, sterilisation and storage of the biofunctionalized medical device without loss of functionality.
Covalent, ionic or adhesive bonds, with or without spacers, can be engineered. Biocoatings with customer-specific elution properties are also available.
The technology has been used with diagnostic catheters, and usability studies are being prepared for wound-care products, said Scholl. Currently, Leukocare tailors the technology to specific molecules. In about a year, Scholl expects to have a standard solution available.Norbert Sparrow